Market Overview - As of January 19, the Shanghai Composite Index closed at 4114.00 points, up 12.09 points, with a gain of 0.29% [1] - The Shenzhen Component Index closed at 14294.05 points, up 12.97 points, with a gain of 0.09% [1] - The ChiNext Index closed at 3337.61 points, down 23.41 points, with a decline of 0.70% [1] Stock Performance - A total of 86 A-shares had a turnover rate exceeding 20%, indicating significant trading activity [1] - Key stocks with high turnover rates included: - Kema Materials (科马材料) with a turnover rate of 62.05% and a closing price of 40.25 yuan, down 26.75% [1] - Kuntai Co. (坤泰股份) with a turnover rate of 54.99% and a closing price of 24.74 yuan, up 4.70% [1] - Sanbian Technology (三变科技) with a turnover rate of 48.63% and a closing price of 21.97 yuan, up 10.02% [1] - Nabichuan (纳百川) with a turnover rate of 44.29% and a closing price of 80.88 yuan, up 8.83% [1] - Hongxiang Co. (红相股份) with a turnover rate of 40.96% and a closing price of 17.99 yuan, up 15.17% [1] Notable Stocks - Other notable stocks with high turnover rates included: - Kangqiang Electronics (康强电子) at 40.96% turnover, closing at 23.48 yuan, up 7.46% [1] - Fangzheng Electric (方正电机) at 39.47% turnover, closing at 16.53 yuan, up 5.09% [1] - Shuangjie Electric (双杰电气) at 39.16% turnover, closing at 14.82 yuan, up 20.00% [1] - Deen Precision (德恩精工) at 39.15% turnover, closing at 24.19 yuan, up 2.76% [1] - C Zhi Xin (C至信) at 37.80% turnover, closing at 52.04 yuan, down 6.54% [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 0.44 | -18.52% | 80.35万 | 3755.51万 | | 002317 | 众生药业 | 21.67 | -1.95% | 79.70万 | 17.45亿 | | 002424 | ST百灵 | 4.27 | -1.39% | 28.70万 | 1.24亿 | | 300147 | ST香雪 | 9.08 | -1.30% | 7.84万 | 7117.68万 | | 920266 | 生物谷 | 9.36 | -1.27% | 1.07万 | 1002.85万 | | 300158 | 振东制药 | 6.08 | -0.65% | 17.81万 | 1.09亿 | | 600422 | 昆药集团 | 12.82 | -0.62% | 6.94万 | 8895.05万 | | 600436 | 片仔瘦 | 167.82 | -0.52% | 2.31万 | 3.87亿 | | 002349 | ...

Core Viewpoint - *ST Changyao (300391) has experienced significant stock price decline, raising concerns about potential delisting due to continuous financial and operational issues [1][3][4]. Trading Information Summary - As of January 16, 2026, *ST Changyao closed at 0.54 yuan, down 20.59%, with a trading volume of 779,974 shares and a turnover of 45.045 million yuan [1]. - The stock has fallen for four consecutive days, with a cumulative decline of 36.08% year-to-date [1]. - In the last ten trading days, the net outflow of main funds reached 40.3818 million yuan, coinciding with a 36.08% drop in stock price [1]. Fund Flow Summary - On January 16, 2026, the main funds experienced a net outflow of 8.2002 million yuan, while retail investors saw a net inflow of 4.3908 million yuan, indicating a trend of institutional selling and retail buying [2]. 龙虎榜 Summary - *ST Changyao was listed on the "龙虎榜" due to a daily decline of 15% and a cumulative deviation of 30% over three trading days, marking its first appearance on the list in the last five trading days [3]. Company Announcement Summary - The company issued its eighth risk warning regarding potential delisting due to trading, financial issues, and significant legal violations, with the stock price remaining below 1 yuan for eleven consecutive trading days and market capitalization below 300 million yuan [3][4]. - The company confirmed that it has not discovered any major undisclosed information and that its controlling shareholder did not trade shares during the abnormal trading period [4]. - The ninth risk warning reiterated the potential for delisting, citing negative net assets and confirmed financial misreporting from 2021 to 2023, which has been recognized by the China Securities Regulatory Commission [4][5].

证券代码：300391 证券简称：*ST长药 公告编号：2026-007 长江医药控股股份有限公司 关于公司股票可能被终止上市的第九次风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、公司股票可能被实施交易类强制退市。2026年1月16日，长江医药控股 股份有限公司（以下简称"公司"或"长药控股"）股票收盘价格为0.54元/股， 已连续十二个交易日均低于1元；公司股票收盘市值1.89亿元，已连续六个交易 日均低于3亿元。根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规 定，若公司出现连续二十个交易日的股票收盘价均低于1元，或者连续二十个交 易日的股票收盘市值均低于3亿元，公司股票将被终止上市。根据《深圳证券交 易所创业板股票上市规则》第10.7.1条的规定，若公司股票因触及交易类强制 退市规定被实施交易类强制退市，公司股票不进入退市整理期。 2、公司股票可能被实施财务类强制退市。公司股票自2025年4月22日起被 实施退市风险警示和其他风险警示，自2025年12月29日起被叠加实施退市风险 警示。鉴于公司未在2025年12 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2026-008 长江医药控股股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股票交易异常波动情况 长江医药控股股份有限公司（以下简称"公司"或"长药控股"）股票于2026 年1月15日、2026年1月16日连续2个交易日内日收盘价格跌幅偏离值累计-30.25%， 根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情形。 敬请广大投资者注意投资风险。 二、公司关注并核实情况说明 针对本次公司股票交易异常波动，公司董事会就相关事项进行了核实与自查， 具体情况如下： 1、公司前期披露的信息目前不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、经查询、问询，公司、控股股东和实际控制人不存在关于公司的应披露 而未披露的重大事项或处于筹划阶段的重大事项。 4、经问询，本次股票异常波动期间，公司控股股东、实际控制人未发生买 卖公司股票的行为。 5、2025年12月29日，湖北省十堰市中级人 ...

Core Viewpoint - The regulatory scrutiny on accounting firms in China's capital market has intensified significantly, with the China Securities Regulatory Commission (CSRC) imposing substantial penalties to combat financial fraud and enhance market integrity [1][5][6]. Regulatory Actions - In 2024 and 2025, the CSRC penalized a total of 80 accounting firms and 209 individuals, with total fines amounting to 1.073 billion yuan (approximately 10.73 billion) [1]. - The penalties included 30 instances in 2024, totaling 599 million yuan, and 50 instances in 2025, totaling 474 million yuan [1][2]. - The frequency and severity of penalties have increased, with a 66.67% rise in the number of firms penalized in 2025 compared to 2024 [3]. Specific Cases - In September 2024, the CSRC issued a record fine of 325 million yuan against PwC Zhongtian for its audit of Evergrande, which was nearly equivalent to the total fines imposed on over 50 firms in the previous three years [2]. - In December 2025, Yongtuo Accounting Firm became the first firm banned from providing securities services since the implementation of the securities audit registration system in 2020, with a fine of 65.28 million yuan [3]. Individual Accountability - In 2024, 77 individuals were penalized, with fines totaling 29.1 million yuan, and 7 individuals faced bans from the securities market for 3 to 7 years [2]. - In 2025, the number of penalized individuals rose to 132, with total fines of 46.155 million yuan, marking increases of 71.43% and 58.61% respectively [3]. Systemic Improvements - Experts emphasize that strengthening accountability for accounting firms is crucial for building a comprehensive system to prevent financial fraud in the capital market [5][6]. - The CSRC's approach includes a "zero tolerance" policy towards violations, aiming to enhance the quality of audits and ensure the reliability of financial information [6]. Recommendations for Future Actions - Suggestions include implementing a "double penalty" system that holds both firms and individual auditors accountable, increasing fines for serious violations, and establishing a mechanism linking personal integrity records to professional qualifications [7][8]. - There is a call for improved collaboration among regulatory bodies to create a comprehensive accountability system that integrates administrative, civil, and criminal measures against accounting firms [8][9].

证券之星消息，1月16日中药板块较上一交易日下跌0.59%，*ST长药领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600671 | 天目药业 | 18.41 | 4.07% | 4.04万 | | 7418.12万 | | 002317 | 众生药业 | 22.10 | 3.32% | 86.21万 | | 18.54亿 | | 300878 | 维康药业 | 32.84 | 2.34% | 1 6.12万 | | 2.07亿 | | 002864 | 盘龙药业 | 36.60 | 1.86% | 8.27万 | | 2.97亿 | | 301331 | 恩威医药 | 28.96 | 1.79% | 1.86万 | | 5360.93万 | | 002107 | 沃华医药 | 7.49 | 1.49% | 23.71万 | | 1.78亿 | | ...

Core Viewpoint - Small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them more likely to become market leaders [1] Group 1: Market Overview - As of January 15, there are 862 stocks with a circulating market value below 3 billion yuan, and 321 of these have a circulating market value below 2 billion yuan [1] - A total of 1,513 stocks have a total market value below 5 billion yuan, with 485 stocks having a total market value below 3 billion yuan [1] Group 2: Small-cap Stocks Analysis - The three stocks with the smallest circulating market values are *ST长药 at 238 million yuan, *ST奥维 at 305 million yuan, and *ST立方 at 531 million yuan [1] - The three stocks with the smallest total market values are *ST长药 at 238 million yuan, *ST奥维 at 343 million yuan, and *ST立方 at 533 million yuan [1] Group 3: Selected Small-cap Stocks - Notable small-cap stocks include: - *ST长药: Circulating market value of 238 million yuan, total market value of 238 million yuan, and no P/E ratio [1] - *ST奥维: Circulating market value of 305 million yuan, total market value of 343 million yuan, and no P/E ratio [1] - *ST立方: Circulating market value of 531 million yuan, total market value of 533 million yuan, and no P/E ratio [1] - 扬州金泉: Circulating market value of 694 million yuan, total market value of 2.778 billion yuan, P/E ratio of 24.23 [1] - 万得凯: Circulating market value of 753 million yuan, total market value of 2.964 billion yuan, P/E ratio of 26.59 [1] - 播恩集团: Circulating market value of 758 million yuan, total market value of 2.187 billion yuan, and no P/E ratio [1]

Trading Information Summary - The stock of *ST Changyao (300391) closed at 0.68 yuan on January 15, 2026, down 12.82%, with a trading volume of 638,794 shares and a transaction amount of 63.8794 million yuan [1][4] - The stock has experienced a continuous decline for three days, with two days in the last five trading days showing a drop of over 5%, resulting in a cumulative decline of 20.72% for the year [1][4] - In the first ten trading days, the net outflow of main funds reached 34.3049 million yuan, with a cumulative stock price drop of 26.76% during this period [1] Fund Flow Analysis - On January 15, the net outflow of main funds was 10.8822 million yuan, while retail funds saw a net inflow of 4.2771 million yuan [2][4] Company Announcement Summary - Changjiang Pharmaceutical Holdings Co., Ltd. may face delisting due to trading, financial issues, and significant legal violations, as the stock price has been below 1 yuan for ten consecutive trading days and the market capitalization has been below 300 million yuan for four days [3][4] - The company is expected to have a negative net asset by the end of 2025, and its financial report may receive a non-standard opinion, indicating potential financial delisting risks [3][4] - The company has received a preliminary notice of administrative punishment from the China Securities Regulatory Commission due to false records in annual reports from 2021 to 2023, which may trigger mandatory delisting for significant violations [3][4] - The company and its subsidiaries are facing numerous lawsuits, overdue debts, and frozen bank accounts [3]

Core Viewpoint - The A-share market is experiencing significant divergence, with some stocks reaching new highs while others are continuously declining, leading to several stocks falling below the 1 yuan face value, thus facing delisting risks [1][2]. Group 1: Stock Performance - *ST Aowei (002231) recently closed at 0.99 yuan per share, marking the first time its stock price has fallen below 1 yuan [1]. - Other stocks such as *ST Changyao (300391) and *ST Lifang (300344) have also seen their prices drop below 1 yuan, with *ST Changyao currently at 0.68 yuan after a decline of over 60% in the past month [2]. - *ST Lifang's stock price has plummeted from over 5 yuan to 0.83 yuan, representing a cumulative decline of over 80% in less than two months [2]. Group 2: Market Trends - In contrast to the declining stocks, over 200 stocks in the A-share market have reached historical highs in the past month, with more than 160 stocks achieving this milestone in less than 10 trading days since 2026 began [3]. Group 3: Company Issues - Many companies that have fallen into the low-price stock category face various operational issues, leading to multiple delisting risks [4]. - *ST Changyao received a notice from the China Securities Regulatory Commission regarding false records in its annual reports for 2021, 2022, and 2023, which could lead to forced delisting [4]. - Similarly, *ST Lifang has also been notified of potential delisting due to false records in its financial reports [4]. Group 4: Market Insights - Market expert Gui Haoming noted that even in a bullish market, not all stocks will perform well; some may decline due to poor company performance or delisting pressures, indicating a shift from the past trend of simultaneous stock movements [5]. - The decline in stock prices and trading volumes below listing requirements is primarily attributed to operational issues within the companies, emphasizing that performance remains the top priority for investors [5].